Rho Capital Partners’s Mersana Therapeutics MRSN Stock Holding History

Rho Capital Partners’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,858	Closed	-$3M	–	4
2022 Q1	$3.18M	Hold	31,858	–	–	2.2%	3
2021 Q4	$4.95M	Hold	31,858	–	–	3.22%	3
2021 Q3	$7.51M	Hold	31,858	–	–	4.19%	4
2021 Q2	$10.8M	Hold	31,858	–	–	0.99%	6
2021 Q1	$12.9M	Hold	31,858	–	–	1.24%	6
2020 Q4	$21.2M	Hold	31,858	–	–	11.15%	3
2020 Q3	$14.8M	Hold	31,858	–	–	12.35%	3
2020 Q2	$18.6M	Hold	31,858	–	–	12.07%	3
2020 Q1	$4.64M	Hold	31,858	–	–	4.68%	4
2019 Q4	$4.56M	Hold	31,858	–	–	3.47%	4
2019 Q3	$1.26M	Hold	31,858	–	–	1.05%	4
2019 Q2	$3.23M	Hold	31,858	–	–	2.24%	4
2019 Q1	$4.19M	Hold	31,858	–	–	4.43%	3
2018 Q4	$3.25M	Hold	31,858	–	–	4.77%	3
2018 Q3	$7.96M	Hold	31,858	–	–	7.33%	3
2018 Q2	$14.2M	Hold	31,858	–	–	13.61%	3
2018 Q1	$12.6M	Sell	31,858 -863	-3%	-$341K	17.71%	3
2017 Q4	$13.4M	Hold	32,721	–	–	23.36%	2
2017 Q3	$14.1M	Hold	32,721	–	–	22.27%	2
2017 Q2	$11.4M	Buy	+32,721	New	+$11.3M	15.96%	2

Other funds holding MRSN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Rho Capital Partners's MRSN Position: Q2 2022 in Review

Rho Capital Partners sold out of Mersana Therapeutics (MRSN) in Q2 2022, closing a stake of 31,858 shares — an estimated $3M sold.

Rho Capital Partners first reported a position in MRSN in Q2 2017 and held it in 20 quarters. The position peaked at $21.2M in Q4 2020. 126 funds tracked by Wall St. Rank hold MRSN as of Q2 2022.

Rho Capital Partners reported no remaining Mersana Therapeutics position as of Q2 2022 after selling out during the quarter.
Rho Capital Partners sold 31,858 Mersana Therapeutics shares in Q2 2022, an estimated $3M.
Rho Capital Partners first reported a position in Mersana Therapeutics in Q2 2017 and held it in 20 quarters.
Rho Capital Partners's Mersana Therapeutics position peaked at $21.2M in Q4 2020.
126 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2022.

Based on Rho Capital Partners's 13F filing for Q2 2022, filed 1 Aug 2022.